Persistence with a single pill versus two pills of amlodipine and atorvastatin: The Australian experience, 2006-2010

Medical Journal of Australia

Volumn 195, Issue 3, 2011, Pages 134-137

  Simons, Leon A ^a   Ortiz, Michael ^a,b   Calcino, Gordon ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b Abbott Products   (Australia)

^c HI Connections Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POST HOC ANALYSIS; RANDOM SAMPLE;

EID: 79961147894     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb03240.x     Document Type: Article

References (17)

1. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipidlowering drugs. Med J Aust 1996; 164: 208-211.
2. Caro JJ, Salas M, Speckman JI, et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31-37.
3. Simons LA, Simons J, Mcmanus P, Dudley J. Discontinuation rates for use of statins are high. BMJ 2000; 321: 1084.
4. Benner JS, Glynn RJ, Mogun H, et al. Longterm persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-461.
5. Degli Espositi E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439-444.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
7. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007; 20: 72-80.
8. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008; 188: 224-227.
9. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipidlowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000; 25: 445-451.
10. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147-1152.
11. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719.
12. Hussein MA, Chapman RH, Benner JS, et al. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? Am J Cardiovasc Drugs 2010; 10: 193-202.
13. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55: 399-407.
14. After the diagnosis: adherence and persistence with hypertension therapy. Am J Manag Care 2005; 11 (13 Suppl): S395-S399.
15. Nelson MR, Reid CM, Ryan P, et al. Selfreported adherence with medication and cardiovascular disease outcomes in the second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006; 185: 487-489.
16. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2009; 12: 489-497.
17. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord 2010; 10: 29.